Our research presents that dysregulation of PD-1 in CD4+ T cells is integral to the pathogenesis of SSc-ILD and highlights the modulation of the PD-1/PD-L1 axis by MSCs as a crucial therapeutic mechanism. This evidence concerns the gene CD274 and systemic sclerosis.